Clinical trials
Phase 2 Edema trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 3 |
| 2006 | 2 |
| 2008 | 1 |
| 2010 | 6 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Terminated | 2 |
| Unknown status | 2 |
| Active, not recruiting | 2 |
| Suspended | 1 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Jaeb Center for Health Research | 2 |
| Johns Hopkins University | 2 |
| M.D. Anderson Cancer Center | 2 |
| Unity Health Toronto | 2 |
| BioMarck Pharmaceuticals, Ltd. | 1 |
| CardioKine Inc. | 1 |
| ConvaTec Inc. | 1 |
| Hospital General de México Dr. Eduardo Liceaga | 1 |
| IC-MedTech Corporation | 1 |
| Maimónides Biomedical Research Institute of Córdoba | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Edema | 30 |
| Heart Failure | 5 |
| Retinal Diseases | 4 |
| Eye Diseases | 3 |
| Macular Edema | 3 |
| Diabetes Mellitus | 2 |
| Diabetic Retinopathy | 2 |
| Erythema | 2 |
| Inflammatory Breast Neoplasms | 2 |
| Respiratory Distress Syndrome | 2 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.